title: Assessment of the effect of TLR7/8, TLR9 agonists and CD40 ligand on the transformation efficiency of Epstein-Barr virus in human B lymphocytes by limiting dilution assay.
abstract: Infection of human B cells with Epstein-Barr virus (EBV) induces polyclonal activation in almost all infected cells, but a small proportion of infected cells are transformed to immortalized lymphoblastoid cell lines. Since B cells are activated also by CD40 ligand (CD40L) and Toll-like receptor (TLR) agonists via a similar signaling pathway, it is likely that costimulation through these molecules could result in synergistic enhancement of the transformation efficiency of EBV. In this study, the stimulatory effect of TLR7/8 (R848), TLR9 (CpG) agonists and/or CD40L on transformation efficiency of EBV in normal human B cells was assessed using the limiting dilution assay. Costimulation of peripheral blood mononuclear cells (PBMCs) with CpG and R848, but not CD40L, increased significantly the frequency of EBV transformed B cells (p < 0.001). Neither synergistic nor additive effects were observed between TLR agonists and CD40L and also TLR7/8 and TLR9 agonists. Costimulation with R848, CpG and CD40L enhanced the proliferative response of B cells infected with EBV. This effect was more evident when enriched B cells were employed, compared to PBMCs. The promoting effect of TLR agonists stimulation, implies that EBV may take advantage of the genes induced by the TLR stimulation pathway for viral latency and oncogenesis.
authors: Department of Immunology, School of Public Health, Tehran University of Medical Sciences, 14155, Tehran, Iran.
authors: Vahid
authors: V
authors: Younesi
authors: Forough Golsaz
authors: FG
authors: Shirazi
authors: Ali
authors: A
authors: Memarian
authors: Amir
authors: A
authors: Amanzadeh
authors: Mahmood
authors: M
authors: Jeddi-Tehrani
authors: Fazel
authors: F
authors: Shokri
references: Blood. 2008 Feb 1;111(3):1448-55
references: 18006702
references: Int J Pediatr Otorhinolaryngol. 1993 Mar;26(2):149-55
references: 8444556
references: Vox Sang. 2004 Jan;86(1):62-70
references: 14984562
references: J Virol. 2007 Sep;81(18):9748-58
references: 17609264
references: Immunology. 2001 Sep;104(1):75-9
references: 11576223
references: J Exp Med. 1983 Jan 1;157(1):1-14
references: 6294212
references: Nat Rev Immunol. 2008 Dec;8(12):911-22
references: 18989317
references: Biochem Pharmacol. 2008 Feb 1;75(3):589-602
references: 17868652
references: J Immunol. 1991 Feb 1;146(3):936-40
references: 1846385
references: J Clin Invest. 1984 Jun;73(6):1789-95
references: 6327772
references: J Immunol. 2000 Jan 15;164(2):944-53
references: 10623843
references: J Immunol. 2004 Jan 15;172(2):954-63
references: 14707068
references: J Immunol. 2007 Apr 1;178(7):4072-9
references: 17371961
references: J Virol. 2009 Feb;83(3):1474-82
references: 19019960
references: Microbiol Immunol. 2010 Sep;54(9):534-41
references: 20840152
references: Nat Immunol. 2005 Aug;6(8):769-76
references: 15995707
references: Biochem Biophys Res Commun. 2007 Sep 21;361(2):537-42
references: 17662694
references: Virology. 1977 Jan;76(1):152-63
references: 189490
references: Int J Cancer. 2002 Jun 10;99(5):705-12
references: 12115504
references: Cell Prolif. 2005 Feb;38(1):35-45
references: 15679865
references: Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):437-42
references: 11752411
references: Mol Cell Biol. 1995 Apr;15(4):2207-18
references: 7534379
references: Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7836-40
references: 12805559
references: J Immunol. 2005 Aug 1;175(3):1619-27
references: 16034101
references: J Exp Med. 2001 Apr 16;193(8):943-54
references: 11304555
references: In Vitro Cell Dev Biol. 1986 Dec;22(12):689-94
references: 3023278
references: Crit Rev Oncol Hematol. 2003 Jan;45(1):1-36
references: 12482570
references: Nat Immunol. 2011 Jul 19;12(8):695-708
references: 21772278
references: J Leukoc Biol. 2007 Sep;82(3):497-508
references: 17565046
references: J Biol Chem. 1992 Dec 5;267(34):24157-60
references: 1332946
references: Antiviral Res. 1995 Nov;28(3):253-64
references: 8629817
references: Nat Rev Cancer. 2004 Oct;4(10):757-68
references: 15510157
references: Nat Med. 2004 Aug;10(8):871-5
references: 15247913
references: Cell Prolif. 2003 Aug;36(4):191-7
references: 12950388
references: J Clin Invest. 2001 Jan;107(2):143-51
references: 11160127
references: J Exp Med. 1981 Sep 1;154(3):832-9
references: 6268732
references: Viral Immunol. 2005;18(2):267-81
references: 16035939
references: Cell Prolif. 2008 Apr;41(2):292-8
references: 18336473
references: Blood. 2008 Mar 15;111(6):3116-25
references: 18202224
references: Arthritis Rheum. 2005 Aug;52(8):2313-22
references: 16052591
references: J Virol. 2007 Aug;81(15):8016-24
references: 17522215
references: Dev Comp Immunol. 2010 May;34(5):572-8
references: 20051250
references: Cell Microbiol. 2007 Aug;9(8):2055-69
references: 17419714
references: Arthritis Rheum. 2010 Jun;62(6):1693-701
references: 20178121
references: Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10116-21
references: 15218108
references: J Virol. 2003 Aug;77(15):8532-40
references: 12857922
references: Cell Prolif. 2006 Dec;39(6):457-69
references: 17109631
references: J Immunol. 2008 Jan 1;180(1):438-43
references: 18097045
references: Immunology. 2009 Nov;128(3):311-23
references: 20067531
references: J Immunol. 2007 Jan 15;178(2):1164-71
references: 17202381
references: Nat Rev Immunol. 2003 Oct;3(10):801-12
references: 14523386
references: J Immunol. 2006 Dec 1;177(11):8164-70
references: 17114492
references: Blood. 2007 Nov 15;110(10):3715-21
references: 17682125
references: Int J Cancer. 2008 Nov 1;123(9):2113-9
references: 18704934
references: Cancer Res. 2008 Jun 1;68(11):4045-9
references: 18519662
references: J Virol. 2010 Apr;84(7):3612-23
references: 20089650